[(3R)-3-(aminomethyl)pyrrolidin-3-yl]methanol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: [(3R)-3-(aminomethyl)pyrrolidin-3-yl]methanol
• 化学式: C₆H₁₄N₂O
• 分子量: 130.19
• InChiKey: SOCIAWKDLHUOID-ZCFIWIBFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  58.3
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• Pyrazolo[1,5-A]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use
  申请人：CANCER RESEARCH TECHNOLOGY LIMITED

  公开号：US10414772B2

  公开（公告）日：2019-09-17

  Certain pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds that inhibit cycline dependent kinase (CDK) (e.g., CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, CDK13, etc.) are disclosed. Pharmaceutical compositions comprising these compounds, and the use of these compounds and compositions to inhibit CDK; to treat disorders associated with CDK such as those arising from an inappropriate activity, mutation, overexpression, or upstream pathway activation of CDK; or disorders that are ameliorated by the inhibition of CDK; proliferative disorders; cancer; viral infections; neurodegenerative disorders; ischaemia; renal diseases; and cardiovascular disorders are also disclosed. Optionally, the treatment further comprises simultaneous or sequential treatment with a further active agent, e.g., an aromatase inhibitor, an anti-estrogen, a Her2 blocker, a cytotoxic chemotherapeutic agent, etc.

  本发明公开了某些吡唑并[1,5-a]嘧啶-5,7-二胺化合物，这些化合物可抑制细胞周期依赖性激酶（CDK）（如CDK1、CDK2、CDK4、CDK5、CDK6、CDK7、CDK8、CDK9、CDK10、CDK11、CDK12、CDK13等）。还公开了包含这些化合物的药物组合物，以及使用这些化合物和组合物抑制 CDK；治疗与 CDK 相关的疾病，如 CDK 的不适当活性、突变、过表达或上游途径激活引起的疾病；或通过抑制 CDK 可改善的疾病；增殖性疾病；癌症；病毒感染；神经退行性疾病；缺血；肾脏疾病；以及心血管疾病。可选地，治疗还包括同时或连续使用另一种活性剂，如芳香化酶抑制剂、抗雌激素、Her2阻断剂、细胞毒性化疗剂等。
• Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use
  申请人：CANCER RESEARCH TECHNOLOGY LIMITED

  公开号：US10927119B2

  公开（公告）日：2021-02-23

  Certain pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds that inhibit cycline dependent kinase (CDK) (e.g., CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, CDK13, etc.) are disclosed. Pharmaceutical compositions comprising these compounds, and the use of these compounds and compositions to inhibit CDK; to treat disorders associated with CDK such as those arising from an inappropriate activity, mutation, overexpression, or upstream pathway activation of CDK; or disorders that are ameliorated by the inhibition of CDK; proliferative disorders; cancer; viral infections; neurodegenerative disorders; ischaemia; renal diseases; and cardiovascular disorders are also disclosed. Optionally, the treatment further comprises simultaneous or sequential treatment with a further active agent, e.g., an aromatase inhibitor, an anti-estrogen, a Her2 blocker, a cytotoxic chemotherapeutic agent, etc.

  本发明公开了某些吡唑并[1,5-a]嘧啶-5,7-二胺化合物，这些化合物可抑制细胞周期依赖性激酶（CDK）（如CDK1、CDK2、CDK4、CDK5、CDK6、CDK7、CDK8、CDK9、CDK10、CDK11、CDK12、CDK13等）。还公开了包含这些化合物的药物组合物，以及使用这些化合物和组合物抑制 CDK；治疗与 CDK 相关的疾病，如 CDK 的不适当活性、突变、过表达或上游途径激活引起的疾病；或通过抑制 CDK 可改善的疾病；增殖性疾病；癌症；病毒感染；神经退行性疾病；缺血；肾脏疾病；以及心血管疾病。可选地，治疗还包括同时或连续使用另一种活性剂，如芳香化酶抑制剂、抗雌激素、Her2阻断剂、细胞毒性化疗剂等。
• PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE
  申请人：CANCER RESEARCH TECHNOLOGY LIMITED

  公开号：US20200055862A1

  公开（公告）日：2020-02-20

  Certain pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds that inhibit cycline dependent kinase (CDK) (e.g., CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, CDK13, etc.) are disclosed. Pharmaceutical compositions comprising these compounds, and the use of these compounds and compositions to inhibit CDK; to treat disorders associated with CDK such as those arising from an inappropriate activity, mutation, overexpression, or upstream pathway activation of CDK; or disorders that are ameliorated by the inhibition of CDK; proliferative disorders; cancer; viral infections; neurodegenerative disorders; ischaemia; renal diseases; and cardiovascular disorders are also disclosed. Optionally, the treatment further comprises simultaneous or sequential treatment with a further active agent, e.g., an aromatase inhibitor, an anti-estrogen, a Her2 blocker, a cytotoxic chemotherapeutic agent, etc.
• US9932344B2
  申请人：——

  公开号：US9932344B2

  公开（公告）日：2018-04-03